Related references
Note: Only part of the references are listed.Expanding antigen-specific regulatory networks to treat autoimmunity
Xavier Clemente-Casares et al.
NATURE (2016)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Indoleamine 2,3-dioxygenase vaccination
Mads Hald Andersen et al.
ONCOIMMUNOLOGY (2015)
c-Met is a novel tumor associated antigen for T-cell based immunotherapy against NK/T cell lymphoma
Takumi Kumai et al.
ONCOIMMUNOLOGY (2015)
Epigenetic Potentiation of NY-ESO-1 Vaccine Therapy in Human Ovarian Cancer
Kunle Odunsi et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Human Leukocyte Antigen-G Is Frequently Expressed in Glioblastoma and May Be Induced in Vitro by Combined 5-Aza-2′-Deoxycytidine and Interferon-γ Treatments Results from a Multicentric Study
Isabela J. Wastowski et al.
AMERICAN JOURNAL OF PATHOLOGY (2013)
EGFR inhibitors augment antitumour helper T-cell responses of HER family-specific immunotherapy
T. Kumai et al.
BRITISH JOURNAL OF CANCER (2013)
NK cytolysis is dependent on the proportion of HLA-G expression
Bao-Guo Chen et al.
HUMAN IMMUNOLOGY (2013)
The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4+ T cells
Shamaila Munir et al.
ONCOIMMUNOLOGY (2013)
Lymphocyte Cell-Cycle Inhibition by HLA-G Is Mediated by Phosphatase SHP-2 and Acts on the mTOR Pathway
Farah Ketroussi et al.
PLOS ONE (2011)
HLA-G Expression in Human Breast Cancer: Implications for Diagnosis and Prognosis, and Effect on Allocytotoxic Lymphocyte Response After Hormone Treatment In Vitro
Xu He et al.
ANNALS OF SURGICAL ONCOLOGY (2010)
Differentiation of type 1 T regulatory cells (Tr1) by tolerogenic DC-10 requires the IL-10-dependent ILT4/HLA-G pathway
Silvia Gregori et al.
BLOOD (2010)
HLA-E and HLA-G Expression in Classical HLA Class I-Negative Tumors Is of Prognostic Value for Clinical Outcome of Early Breast Cancer Patients
Esther M. de Kruijf et al.
JOURNAL OF IMMUNOLOGY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Demethylating agent 5-aza-2′-deoxycytidine activates HLA-G expression in human leukemia cell lines
K. Polakova et al.
LEUKEMIA RESEARCH (2009)
Expression of human leucocyte antigen G (HLA-G) is associated with prognosis in non-small cell lung cancer
Shang-Mian Yie et al.
LUNG CANCER (2007)
Expression of human leukocyte antigen G (HLA-G) correlates with poor prognosis in gastric carcinoma
Shang-Mian Yie et al.
ANNALS OF SURGICAL ONCOLOGY (2007)
CD4 cells can be more efficient at tumor rejection than CD8 cells
Ainhoa Perez-Diez et al.
BLOOD (2007)
Descriptive analysis of estrogen receptor (ER)negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype - A population-based study from the California Cancer Registry
Katrina R. Bauer et al.
CANCER (2007)
Expression of HLA-G in malignant mesothelioma and clinically aggressive breast carcinoma
Lilach Kleinberg et al.
VIRCHOWS ARCHIV (2006)
Altered expression of cellular membrane molecules of HLA-DR, HLA-G and CD99 in cervical intraepithelial neoplasias and invasive squamous cell carcinoma
JH Zhou et al.
LIFE SCIENCES (2006)
Soluble HLA-G inhibits cell cycle progression in human alloreactive T lymphocytes
R Bahri et al.
JOURNAL OF IMMUNOLOGY (2006)
HLA-G gene activation in tumor cells involves cis-acting epigenetic changes
G Mouillot et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Expression of HLA-G in inflammatory bowel disease provides a potential way to distinguish between ulcerative colitis and Crohn's disease
MI Torres et al.
INTERNATIONAL IMMUNOLOGY (2004)
Tumor-derived MUC1 mucins interact with differentiating monocytes and induce IL-10high IL-12low regulatory dendritic cell
P Monti et al.
JOURNAL OF IMMUNOLOGY (2004)
Major histocompatibility complex class II-restricted presentation of a cytosolic antigen by autophagy
F Nimmerjahn et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2003)
An essential function of tapasin in quality control of HLA-G molecules
B Park et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
HLA-G gene repression is reversed by demethylation
P Moreau et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
KIR2DL4 (CD158d), an NK cell-activating receptor with inhibitory potential
M Faure et al.
JOURNAL OF IMMUNOLOGY (2002)
Soluble HLA-G protein secreted by allo-specific CD4+ T cells suppresses the allo-proliferative response:: A CD4+ T cell regulatory mechanism
N Lila et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Human leukocyte antigen G up-regulation in lung cancer associates with high-grade histology, human leukocyte antigen class I loss and interleukin-10 production
M Urosevic et al.
AMERICAN JOURNAL OF PATHOLOGY (2001)
HLA-G1 co-expression boosts the HLA class I-mediated NK lysis inhibition
B Riteau et al.
INTERNATIONAL IMMUNOLOGY (2001)
HLA-G has a concentration-dependent effect on the generation of an allo-CTL response
K Kapasi et al.
IMMUNOLOGY (2000)
Cytoplasmic processing is a prerequisite for presentation of an endogenous antigen by major histocompatibility complex class II proteins
JD Lich et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Share Paper
